Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial
Autore:
Schmidinger, M; Stager, G; Wenzel, C; Locker, GJ; Budinsky, AC; Brodowicz, T; Kramer, G; Marberger, M; Zielinski, CC;
Indirizzi:
Univ Hosp, Div Clin Oncol, Vienna, Austria Univ Hosp Vienna AustriaUniv Hosp, Div Clin Oncol, Vienna, Austria Univ Hosp, Dept Med 1, Chair Med Expt Oncol, Vienna, Austria Univ Hosp Vienna Austria t Med 1, Chair Med Expt Oncol, Vienna, Austria Ludwig Boltzmann Inst Clin Expt Oncol, Vienna, Austria Ludwig Boltzmann Inst Clin Expt Oncol Vienna Austria l, Vienna, Austria
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 257 - 262
SICI:
1524-9557(200105/06)24:3<257:SAOIGA>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING-FACTOR; RECOMBINANT HUMAN INTERLEUKIN-2; TUMOR NECROSIS FACTOR; PULMONARY METASTASES; DOSE INTERLEUKIN-2; CANCER-PATIENTS; IMMUNOTHERAPY; THERAPY; ALPHA; COMBINATION;
Keywords:
renal cell carcinoma; GM-CSF; immunotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Stager, G Univ Vienna, Dept Med 1, Div Oncol, 18-20 Waehringer Guertel, A-1090 Vienna, Austria Univ Vienna 18-20 Waehringer Guertel Vienna Austria A-1090 tria
Citazione:
M. Schmidinger et al., "Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial", J IMMUNOTH, 24(3), 2001, pp. 257-262

Abstract

Various cytokine combinations have been tested for efficacy in the treatment of metastatic renal cell carcinoma (MRCC). Because several immunologic synergisms between granulocyte-macrophage colony-stimulating-factor (GM-CSF)and interleukin-2 (IL-2) have been demonstrated, this phase II trial was conducted on the efficacy and toxicity of subcutaneous, sequentially administered, interferon-gamma (IFN gamma), GM-CSF, and IL-2. Fifty-five consecutive patients with MRCC were treated with 100 mug recombinant IFN gamma 1b administered thrice weekly during weeks 1 and 4, followed by 400 mug GM-CSF on 5 consecutive days during weeks 2 and 5. In weeks 3 and 6, patients received 4.5 MU recombinant IL-2 from days 1 to 4. The treatment was repeated every 8 weeks. Five (10%) of patients experienced an objective response (complete response [CR]: 2%, partial response [PR]: 8%). Fourteen (26%) patientshad stable disease with a median duration of 19 months (6-47+). The medianoverall survival was 12 months (range: 0.3-44 months), No toxicity greaterthan World Health Organization grade II was observed, with fever (43%) anderythema (43%) being the most frequent side effects. Compared with other phase II trials with IFN gamma and IL-2 alone, the addition of GM-CSF failedto improve response or survival in patients with MRCC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:31:00